Clovamide and rosmarinic acid induce neuroprotective effects in in vitro models of neuronal death

British Journal of Pharmacology

Volumn 157, Issue 6, 2009, Pages 1072-1084

  Fallarini, S ^a   Miglio, G ^b   Paoletti, T ^a   Minassi, A ^a   Amoruso, A ^a   Bardelli, C ^a   Brunelleschi, S ^a   Lombardi, G ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Excitotoxicity; Ischaemia reperfusion; Neuroprotection; NF kB; Oxidative stress; Polyphenolics; PPARg

Indexed keywords

ALPHA TOCOPHEROL; CALCIUM ION; CLOVAMIDE; DIZOCILPINE; GLUCOSE; GLUTAMIC ACID; GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTATE DEHYDROGENASE; NEUROPROTECTIVE AGENT; OXYGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POLYPHENOL; PROTEIN C FOS; PROTEIN C JUN; ROSMARINIC ACID; TERT BUTYL HYDROPEROXIDE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; EXCITOTOXICITY; GENE EXPRESSION; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; ISCHEMIA; LIPID PEROXIDATION; NERVE CELL NECROSIS; NEUROBLASTOMA CELL; NEUROPROTECTION; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REPERFUSION INJURY;

CELL DEATH; CELL DIFFERENTIATION; CELL LINE, TUMOR; CINNAMATES; DEPSIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NEURONS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; TYROSINE;

EID: 70349149104     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00213.x     Document Type: Article

References (72)

1. van Acker SA, Koymans LM, Bast A (1993). Molecular pharmacology of vitamin E: structural aspects of antioxidant activity. Free Radic Biol Med 15: 311-328.
2. Amoroso S, Gioielli A, Cataldi M, Di Renzo G, Annunziato L (1999). In the neuronal cell line SH-SY5Y, oxidative stress-induced free radical overproduction causes cell death without any participation of intra-cellular Ca (2+) increase. Biochem Biophys Acta 1452: 151-160.
3. Amoruso A, Bardelli C, Gunella G, Fresu LG, Ferrero V, Brunelleschi S (2007). Quantification of PPAR-gamma protein in monocyte/ macrophages from healthy smokers and non-smokers: a possible direct effect of nicotine. Life Sci 81: 906-915.
4. Arlorio M, Locatelli M, Travaglia F, Coïsson J-D, Del Grosso E, Minassi A et al. (2008). Roasting impact on the contents of clovamide (N-caffeoyl-L-DOPA) and the antioxidant activity of cocoa beans (Theobroma cacao L.). Food Chem 106: 967-975.
5. Baba S, Osakabe N, Natsume M, Terao J (2004). Orally administered rosmarinic acid is present as the conjugated and/or methylated forms in plasma, and is degraded and metabolized to conjugated forms of caffeic acid, ferulic acid and m-coumaric acid. Life Sci 75: 165-178.
6. Bano D, Nicotera P (2007). Ca2+ signals and neuronal death in brain ischemia. Stroke 38: 674-676.
7. Bardelli C, Gunella G, Varsaldi F, Balbo P, Del Boca E, Bernardone IS et al. (2005). Expression of functional NK1 receptors in human alveolar macrophages: superoxide anion production, cytokine release and involvement of NF-kappaB pathway. Br J Pharmacol 145: 385-396.
8. Barnham KJ, Masters CL, Bush AI (2004). Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 3: 205-214.
9. Beal MF, Hyman BT, Koroshetz W (1993). Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci 16: 125-131.
10. Benedetti E, Papineschi F, Vergamini P, Consolini R, Spremolla G (1984). Analytical infrared spectral differences between human normal and leukaemic cells (CLL)-I. Leuk Res 8: 483-489.
11. Biedler JL, Roffler-Tarlov S, Schachner M, Freedman LS (1978). Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res 38: 3751-3757.
12. Choi DW (1988). Glutamate neurotoxicity and diseases of the nervous system. Neuron 1: 623-634.
13. Choi DW (1992). Excitotoxic cell death. J Neurobiol 23: 1261-1276.
14. Choi DW, Rothman SM (1990). The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci 13: 171-182.
15. Clifford MN, Kellard B, Ah-Sing E (1989). Caffeoyltyrosine from green robusta coffee beans. Phytochemistry 28: 1989-1990.
16. Culman J, Zhao Y, Gohlke P, Herdegen T (2007). PPAR-gamma: therapeutic target for ischemic stroke. Trends Pharmacol Sci 28: 244-249.
17. Daynes RA, Jones DC (2002). Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2: 748-759.
18. Dehmer T, Heneka MT, Sastre M, Dichgans J, Schulz JB (2004). Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem 88: 494-501.
19. Engelhart MJ, Geerlings MI, Ruitenberg A, van Swieten JC, Hofman A, Witteman JC et al. (2002). Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 287: 3223-3229.
20. Fang Y-Z, Yang S, Wu G (2002). Free radicals, antioxidant, and nutrition. Nutrition 18: 872-879.
21. Gassen M, Youdim MB (1999). Free radical scavengers: chemical concepts and clinical relevance. J Neural Transm Suppl 56: 193-210.
22. Gould E (2007). How widespread is adult neurogenesis in mammals? Nat Rev Neurosci 8: 481-488.
23. van Heerden FR, Brandt EV, Roux DG (1980). Isolation and synthesis of trans-and cis-(-)-clovamides and their deoxy analogues from the bark of Dalbergia melanoxylon. Phytochemistry 19: 2125-12119
24. Hoyt KR, Gallagher AJ, Hastings TG, Reynolds IJ (1997). Characterization of hydrogen peroxide toxicity in cultured rat forebrain neurons. Neurochem Res 22: 333-340.
25. Hughes P, Dragunow M (1995). Induction of immediate-early genes and the control of neurotransmitter-regulated gene expression within the nervous system. Pharmacol Rev 47: 133-178.
26. Jung TW, Lee JY, Shim WS, Kang ES, Kim SK, Ahn CW et al. (2007). Rosiglitazone protects human neuroblastoma SH-SY5Y cells against MPP+ induced citotoxicity via inhibition of mitochondrial dysfunction and ROS production. J Neurol Sci 253: 53-60.
27. Kang MA, Yun SY, Won J (2003). Rosmarinic acid inhibits Ca2+-dependent pathways of T-cell antigen receptor-mediated signaling by inhibiting the PLC-gamma 1 and Itk activity. Blood 101: 3534-3542.
28. van Kessel KP, Kalter ES, Verhoef J (1986). Rosmarinic acid inhibits external oxidative effects of human polymorphonuclear granulo-cytes. Agents Actions 17: 375-376.
29. Kim EJ, Park KS, Chung SY, Sheen YY, Moon DC, Song YS et al. (2003). Peroxisome proliferator-activated receptor-gamma activator 15-deoxy-Delta12,14- prostaglandin J2 inhibits neuroblastoma cell growth through induction of apoptosis: association with extracellular signal-regulated kinase signal pathway. J Pharmacol Exp Ther 307: 505-517.
30. Kim JY, Park SJ, Yun KJ, Cho YW, Park HJ, Lee KT (2008). Isoliquiriti-genin isolated from the roots of Glycyrrhiza uralensis inhibits LPS-induced iNOS and COX-2 expression via the attenuation of NF-kappaB in RAW 264.7 macrophages. Eur J Pharmacol 584: 175-184.
31. Kim YS, Sheldon RA, Elliott BR, Liu Q, Ferriero DM, Täuber MG (1995). Brain injury in experimental neonatal meningitis due to group B streptococci. J Neuropathol Exp Neurol 54: 531-539.
32. Konishi Y, Hitomi Y, Yoshida M, Yoshioka E (2005). Pharmacokinetic study of caffeic and rosmarinic acids in rats after oral administration. J Agric Food Chem 53: 4740-4746.
33. Lidwell K, Griffiths R (2000). Possible role for the FosB/JunD AP-1 transcription factor complex in glutamate-mediated excitotoxicity in cultured cerebellar granule cells. J Neurosci Res 62: 427-439.
34. Lipton P (1999). Ischemic cell death in brain neurons. Physiol Rev 79: 1431-1568.
35. Lipton SA, Rosenberg PA (1994). Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 330: 613-622.
36. Lombardi G, Varsaldi F, Miglio G, Papini MG, Battaglia A, Canonico PL (2002). Cabergoline prevents necrotic neuronal death in an in vitro model of oxidative stress. Eur J Pharmacol 457: 95-98.
37. Lombardi G, Miglio G, Varsaldi F, Minassi A, Appendino G (2007). Oxyhomologation of the amide bond potentiates neuroprotective effects of the endolipid N-palmitoylethanolamine. J Pharmacol Exp Ther 320: 599-606.
38. Mattson MP (2007). Calcium and neurodegeneration. Aging Cell 6: 337-350.
39. Mehta SL, Manhas N, Raghubir R (2007). Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res Rev 54: 34-66.
40. Mémet S (2006). NF-kB functions in the nervous system: from development to disease. Biochem Pharmacol 72: 1180-11165
41. Miglio G, Varsaldi F, Francioli E, Battaglia A, Canonico PL, Lombardi G (2004). Cabergoline protects SH-SY5Y neuronal cells in an in vitro model of ischemia. Eur J Pharmacol 489: 157-165.
42. Miglio G, Varsaldi F, Lombardi G (2005). Human T lymphocytes express N-methyl-D-aspartate receptors functionally active in controlling T cell activation. Biochem Biophys Res Commun 338: 1875-1883.
43. Miyamoto Y, Koh YH, Park YS, Fujiwara N, Sakiyama H, Misonou Y et al. (2003). Oxidative stress caused by inactivation of glutathione peroxidase and adaptive responses. Biol Chem 384: 567-574.
44. Nair VD, Niznik HB, Mishra RK (1996). NMDA and dopamine D2L receptor interaction in human neuroblastoma SH-SY5Y cells involves tyrosine kinase and phosphatase. Neuroreport 7: 2937-2940.
45. Olney JW (1986). Inciting excitotoxic cytocide among central neurons. Adv Exp Med Biol 203: 631-645.
46. Park JB (2005). N-coumaroyldopamine and N-caffeoyldopamine increase cAMP via beta 2 adrenoceptors in myelocytic U937 cells. FASEB J 19: 497-502.
47. Park JB, Schoene N (2003). N-Caffeoyltyramine arrests growth of U937 and Jurkat cells by inhibiting protein tyrosine phosphorylation and inducing caspase-3. Cancer Lett 202: 161-171.
48. Park JB, Schoene N (2006). Clovamide-type phenylpropenoic acid amides, N-coumaroyldopamine and N-caffeoyldopamine, inhibit platelet-leukocyte interactions via suppressing P-selectin expression. J Pharmacol Exp Ther 317: 813-819.
49. Pellegrini-Giampietro DE, Cherici G, Alesiani M, Carlà V, Moroni F (1988). Excitatory amino acid release from rat hippocampal slices as a consequence of free-radical formation. J Neurochem 51: 1960-1963.
50. Petersen M, Simmonds MS (2003). Rosmarinic acid. Phytochemistry 62: 121-125.
51. Pizzi M, Spano P (2006). Distinct roles of diverse nuclear factor-kB complexes in neuropathological mechanisms. Eur J Pharmacol 545: 22-28.
52. Pláteník J, Kuramoto N, Yoneda Y (2000). Molecular mechanisms associated with long-term consolidation of the NMDA signals. Life Sci 67: 335-364.
53. Raivich G, Behrens A (2006). Role of the AP-1 transcription factor c-Jun in developing, adult and injured brain. Prog Neurobiol 78: 347-363.
54. Sanbongi C, Osakabe N, Natsume M, Takizawa T, Gomi S, Osawa T (1998). Antioxidative Polyphenols Isolated from Theobroma cacao. J Agric Food Chem 46: 454-457.
55. Sayre LM, Perry G, Smith MA (2008). Oxidative stress and neurotox-icity. Chem Res Toxicol 21: 172-188.
56. Al-Sereiti MR, Abu-Amer KM, Sen P (1999). Pharmacology of rosemary (Rosmarinus officinalis Linn.) and its therapeutic potentials. Indian J Exp Biol 37: 124-130.
57. Schütz B, Reimann J, Dumitrescu-Ozimek L, Kappes-Horn K, Landreth GE, Schürmann B et al. (2005). The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosislike symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci 25: 7805-7812.
58. Shan Y, Carlock LR, Walker PD (1997). NMDA receptor overstimula-tion triggers a prolonged wave of immediate early gene expression: relationship to excitotoxicity. Exp Neurol 144: 406-415.
59. Soobrattee MA, Neergheen VS, Luximon-Ramma A, Aruoma OI, Bahorun T (2005). Phenolics as potential antioxidant therapeutic agents: mechanism and actions. Mutat Res 579: 200-213.
60. Steele M, Stuchbury G, Münch G (2007). The molecular basis of the prevention of Alzheimer's disease through healthy nutrition. Exp Gerontol 42: 28-36.
61. Tormos C, Javier Chaves F, Garcia MJ, Garrido F, Jover R, O'Connor JE et al. (2004). Role of glutathione in the induction of apoptosis and c-fos and c-jun mRNAs by oxidative stress in tumor cells. Cancer Lett 208: 103-113.
62. Trushina E, McMurray CT (2007). Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases. Neuroscience 145: 1233-1248.
63. Valentiner U, Carlsson M, Erttmann R, Hildebrandt H, Schumacher U (2005). Ligands for the peroxisome proliferator-activated receptor-gamma have inhibitory effects on growth of human neuroblastoma cells in vitro. Toxicology 213: 157-168.
64. Vanlangenakker N, Berghe TV, Krysko DV, Festjens N, Vandenabeele P (2008). Molecular mechanisms and pathophysiology of necrotic cell death. Curr Mol Med 8: 207-220.
65. White BC, Sullivan JM, DeGracia DJ, O'Neil BJ, Neumar RW, Grossman LI et al. (2000). Brain ischemia and reperfusion: molecular mechanisms of neuronal injury. J Neurol Sci 179: 1-33.
66. Williams MJ, Sutherland WH, Whelan AP, McCormick MP, de Jong SA (2004). Acute effect of drinking red and white wines on circulating levels of inflammation-sensitive molecules in men with coronary artery disease. Metabolism 53: 318-323.
67. Wong EH, Kemp JA, Priestley T, Knight AR, Woodruff GN, Iversen LL (1986). The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc Natl Acad Sci U S A 83: 7104-7108.
68. Yoshihara T, Yoshikawa H, Sakamura S, Sakuma T (1974). Clovamides. L-Dopa conjugated with trans-and cis-caffeic acids in red clover (Trifolium pratense). Agric Biol Chem 38: 1107-1109.
69. Yoshihara T, Yoshikawa H, Kunimatsu S, Sakamura S, Sakuma T (1977). New amino acid derivatives conjugated with caffeic acid and DOPA from red clover (Trifolium pratense). Agric Biol Chem 41: 1679-1684.
70. Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT et al. (2004). Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol 61: 82-88.
71. Zheng W, Wang SY (2001). Antioxidant activity and phenolic compounds in selected herbs. J Agric Food Chem 49: 5165-5170.
72. Zipp F, Aktas O (2006). The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci 29: 518-527.